These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 23916259)

  • 1. Hit-to-lead optimization and kinase selectivity of imidazo[1,2-a]quinoxalin-4-amine derived JNK1 inhibitors.
    Li B; Cociorva OM; Nomanbhoy T; Weissig H; Li Q; Nakamura K; Liyanage M; Zhang MC; Shih AY; Aban A; Hu Y; Cajica J; Pham L; Kozarich JW; Shreder KR
    Bioorg Med Chem Lett; 2013 Sep; 23(18):5217-22. PubMed ID: 23916259
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Imidazo[1,2-a]pyrazine, Imidazo[1,5-a]quinoxaline and Pyrazolo[1,5-a]quinoxaline derivatives as IKK1 and IKK2 inhibitors.
    Patinote C; Bou Karroum N; Moarbess G; Deleuze-Masquefa C; Hadj-Kaddour K; Cuq P; Diab-Assaf M; Kassab I; Bonnet PA
    Eur J Med Chem; 2017 Sep; 138():909-919. PubMed ID: 28750313
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of amino-pyrimidine inhibitors of c-Jun N-terminal kinase (JNK): kinase profiling guided optimization of a 1,2,3-benzotriazole lead.
    Palmer WS; Alam M; Arzeno HB; Chang KC; Dunn JP; Goldstein DM; Gong L; Goyal B; Hermann JC; Hogg JH; Hsieh G; Jahangir A; Janson C; Jin S; Ursula Kammlott R; Kuglstatter A; Lukacs C; Michoud C; Niu L; Reuter DC; Shao A; Silva T; Trejo-Martin TA; Stein K; Tan YC; Tivitmahaisoon P; Tran P; Wagner P; Weller P; Wu SY
    Bioorg Med Chem Lett; 2013 Mar; 23(5):1486-92. PubMed ID: 23352510
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and biological evaluation of novel substituted pyrrolo[1,2-a]quinoxaline derivatives as inhibitors of the human protein kinase CK2.
    Guillon J; Le Borgne M; Rimbault C; Moreau S; Savrimoutou S; Pinaud N; Baratin S; Marchivie M; Roche S; Bollacke A; Pecci A; Alvarez L; Desplat V; Jose J
    Eur J Med Chem; 2013 Jul; 65():205-22. PubMed ID: 23711832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of imidazo[1,2-a]pyrazine-based Aurora kinase inhibitors.
    Belanger DB; Curran PJ; Hruza A; Voigt J; Meng Z; Mandal AK; Siddiqui MA; Basso AD; Gray K
    Bioorg Med Chem Lett; 2010 Sep; 20(17):5170-4. PubMed ID: 20674350
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of a novel series of 4-quinolone JNK inhibitors.
    Gong L; Tan YC; Boice G; Abbot S; McCaleb K; Iyer P; Zuo F; Dal Porto J; Wong B; Jin S; Chang A; Tran P; Hsieh G; Niu L; Shao A; Reuter D; Lukacs CM; Ursula Kammlott R; Kuglstatter A; Goldstein D
    Bioorg Med Chem Lett; 2012 Dec; 22(24):7381-7. PubMed ID: 23142618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery and characterization of non-ATP site inhibitors of the mitogen activated protein (MAP) kinases.
    Comess KM; Sun C; Abad-Zapatero C; Goedken ER; Gum RJ; Borhani DW; Argiriadi M; Groebe DR; Jia Y; Clampit JE; Haasch DL; Smith HT; Wang S; Song D; Coen ML; Cloutier TE; Tang H; Cheng X; Quinn C; Liu B; Xin Z; Liu G; Fry EH; Stoll V; Ng TI; Banach D; Marcotte D; Burns DJ; Calderwood DJ; Hajduk PJ
    ACS Chem Biol; 2011 Mar; 6(3):234-44. PubMed ID: 21090814
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Imidazo[1,5-a]quinoxalines as irreversible BTK inhibitors for the treatment of rheumatoid arthritis.
    Kim KH; Maderna A; Schnute ME; Hegen M; Mohan S; Miyashiro J; Lin L; Li E; Keegan S; Lussier J; Wrocklage C; Nickerson-Nutter CL; Wittwer AJ; Soutter H; Caspers N; Han S; Kurumbail R; Dunussi-Joannopoulos K; Douhan J; Wissner A
    Bioorg Med Chem Lett; 2011 Nov; 21(21):6258-63. PubMed ID: 21958547
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design and synthesis of 6-anilinoindazoles as selective inhibitors of c-Jun N-terminal kinase-3.
    Swahn BM; Huerta F; Kallin E; Malmström J; Weigelt T; Viklund J; Womack P; Xue Y; Ohberg L
    Bioorg Med Chem Lett; 2005 Nov; 15(22):5095-9. PubMed ID: 16140012
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of imidazo[1,2-b]pyridazine derivatives as IKKbeta inhibitors. Part 1: Hit-to-lead study and structure-activity relationship.
    Shimizu H; Tanaka S; Toki T; Yasumatsu I; Akimoto T; Morishita K; Yamasaki T; Yasukochi T; Iimura S
    Bioorg Med Chem Lett; 2010 Sep; 20(17):5113-8. PubMed ID: 20675134
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exploration of 1-(3-chloro-4-(4-oxo-4H-chromen-2-yl)phenyl)-3-phenylurea derivatives as selective dual inhibitors of Raf1 and JNK1 kinases for anti-tumor treatment.
    Jin F; Gao D; Zhang C; Liu F; Chu B; Chen Y; Chen YZ; Tan C; Jiang Y
    Bioorg Med Chem; 2013 Feb; 21(3):824-31. PubMed ID: 23260578
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design and synthesis of 1-aryl-5-anilinoindazoles as c-Jun N-terminal kinase inhibitors.
    Jiang R; Frackowiak B; Shin Y; Song X; Chen W; Lin L; Cameron MD; Duckett DR; Kamenecka TM
    Bioorg Med Chem Lett; 2013 May; 23(9):2683-7. PubMed ID: 23518277
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pyridinylquinoxalines and pyridinylpyridopyrazines as lead compounds for novel p38 alpha mitogen-activated protein kinase inhibitors.
    Koch P; Jahns H; Schattel V; Goettert M; Laufer S
    J Med Chem; 2010 Feb; 53(3):1128-37. PubMed ID: 20078117
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, synthesis and biological evaluation of type-II VEGFR-2 inhibitors based on quinoxaline scaffold.
    Shahin MI; Abou El Ella DA; Ismail NS; Abouzid KA
    Bioorg Chem; 2014 Oct; 56():16-26. PubMed ID: 24922538
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and SAR of 4-substituted-2-aminopyrimidines as novel c-Jun N-terminal kinase (JNK) inhibitors.
    Humphries PS; Lafontaine JA; Agree CS; Alexander D; Chen P; Do QQ; Li LY; Lunney EA; Rajapakse RJ; Siegel K; Timofeevski SL; Wang T; Wilhite DM
    Bioorg Med Chem Lett; 2009 Apr; 19(8):2099-102. PubMed ID: 19327989
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure based design of novel 6,5 heterobicyclic mitogen-activated protein kinase kinase (MEK) inhibitors leading to the discovery of imidazo[1,5-a] pyrazine G-479.
    Robarge KD; Lee W; Eigenbrot C; Ultsch M; Wiesmann C; Heald R; Price S; Hewitt J; Jackson P; Savy P; Burton B; Choo EF; Pang J; Boggs J; Yang A; Yang X; Baumgardner M
    Bioorg Med Chem Lett; 2014 Oct; 24(19):4714-4723. PubMed ID: 25193232
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibiting NF-κB-inducing kinase (NIK): discovery, structure-based design, synthesis, structure-activity relationship, and co-crystal structures.
    Li K; McGee LR; Fisher B; Sudom A; Liu J; Rubenstein SM; Anwer MK; Cushing TD; Shin Y; Ayres M; Lee F; Eksterowicz J; Faulder P; Waszkowycz B; Plotnikova O; Farrelly E; Xiao SH; Chen G; Wang Z
    Bioorg Med Chem Lett; 2013 Mar; 23(5):1238-44. PubMed ID: 23374866
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and SAR studies of imidazo-[1,2-a]-pyrazine Aurora kinase inhibitors with improved off-target kinase selectivity.
    Voss ME; Rainka MP; Fleming M; Peterson LH; Belanger DB; Siddiqui MA; Hruza A; Voigt J; Gray K; Basso AD
    Bioorg Med Chem Lett; 2012 May; 22(10):3544-9. PubMed ID: 22503250
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure-based design of novel quinoxaline-2-carboxylic acids and analogues as Pim-1 inhibitors.
    Oyallon B; Brachet-Botineau M; Logé C; Bonnet P; Souab M; Robert T; Ruchaud S; Bach S; Berthelot P; Gouilleux F; Viaud-Massuard MC; Denevault-Sabourin C
    Eur J Med Chem; 2018 Jun; 154():101-109. PubMed ID: 29778892
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design and synthesis of 7-hydroxy-1H-benzoimidazole derivatives as novel inhibitors of glycogen synthase kinase-3beta.
    Shin D; Lee SC; Heo YS; Lee WY; Cho YS; Kim YE; Hyun YL; Cho JM; Lee YS; Ro S
    Bioorg Med Chem Lett; 2007 Oct; 17(20):5686-9. PubMed ID: 17764934
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.